{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:36:46Z","timestamp":1780321006167,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1479-5876-12-191","type":"journal-article","created":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T11:01:34Z","timestamp":1404903694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Ipilimumab augments antitumor activity of bispecific antibody-armed T cells"],"prefix":"10.1186","volume":"12","author":[{"given":"Hiroshi","family":"Yano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse N","family":"Tomaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsig","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Deol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence G","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,9]]},"reference":[{"key":"1901_CR1","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-12-3381","volume":"73","author":"S Kalathil","year":"2013","unstructured":"Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y: Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013, 73: 2435-2444.","journal-title":"Cancer Res"},{"key":"1901_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/ijc.25681","volume":"129","author":"N Suarez","year":"2011","unstructured":"Suarez N, Alfaro C, Dubrot J, Palazon A, Bolanos E, Erro L, Hervas-Stubbs S, Martinez-Forero I, Morales-Kastresana A, Martin-Algarra S, Sangro B, Lecanda F, Perez-Gracia JL, Gonzalez A, Melero I: Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. International Journal of Cancer. 2011, 129: 374-386.","journal-title":"International Journal of Cancer"},{"key":"1901_CR3","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.4049\/jimmunol.171.7.3459","volume":"171","author":"F Maszyna","year":"2003","unstructured":"Maszyna F, Hoff H, Kunkel D, Radbruch A, Brunner-Weinzierl MC: Diversity of clonal T cell proliferation is mediated by differential expression of CD152 (CTLA-4) on the cell surface of activated individual T lymphocytes. J Immunol. 2003, 171: 3459-3466.","journal-title":"J Immunol"},{"key":"1901_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2249.2004.02478.x","volume":"136","author":"CB Jago","year":"2004","unstructured":"Jago CB, Yates J, Camara NO, Lechler RI, Lombardi G: Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol. 2004, 136: 463-471.","journal-title":"Clin Exp Immunol"},{"key":"1901_CR5","doi-asserted-by":"publisher","first-page":"15417","DOI":"10.1074\/jbc.270.25.15417","volume":"270","author":"PS Linsley","year":"1995","unstructured":"Linsley PS, Nadler SG, Bajorath J, Peach R, Leung HT, Rogers J, Bradshaw J, Stebbins M, Leytze G, Brady W, Malacko AR, Marquardt H, Shaw SY: Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules. The Journal of Biological Chemistry. 1995, 270: 15417-15424.","journal-title":"The Journal of Biological Chemistry"},{"key":"1901_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.185.3.393","volume":"185","author":"PA van der Merwe","year":"1997","unstructured":"van der Merwe PA, Bodian DL, Daenke S, Linsley PS, Davis SJ: CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics. J Exp Med. 1997, 185: 393-404.","journal-title":"J Exp Med"},{"key":"1901_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","volume":"18","author":"KS Peggs","year":"2006","unstructured":"Peggs KS, Quezada SA, Korman AJ, Allison JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006, 18: 206-213.","journal-title":"Curr Opin Immunol"},{"key":"1901_CR8","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1093\/JI\/187.7.3466","volume":"187","author":"TL Walunas","year":"2011","unstructured":"Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA: Pillars article: CTLA-4 Can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405\u2013413. J Immunol. 2011, 187: 3466-3474.","journal-title":"J Immunol"},{"key":"1901_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel MF, Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995, 182: 459-465.","journal-title":"J Exp Med"},{"key":"1901_CR10","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996, 271: 1734-1736.","journal-title":"Science"},{"key":"1901_CR11","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-06-2070","volume":"13","author":"PE Fecci","year":"2007","unstructured":"Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH: Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007, 13: 2158-2167.","journal-title":"Clin Cancer Res"},{"key":"1901_CR12","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.1016\/j.vaccine.2010.07.066","volume":"28","author":"MR Sorensen","year":"2010","unstructured":"Sorensen MR, Holst PJ, Steffensen MA, Christensen JP, Thomsen AR: Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine. 2010, 28: 6757-6764.","journal-title":"Vaccine"},{"key":"1901_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1084\/jem.194.6.823","volume":"194","author":"RP Sutmuller","year":"2001","unstructured":"Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001, 194: 823-832.","journal-title":"J Exp Med"},{"key":"1901_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine. 2010, 363: 711-723.","journal-title":"The New England Journal of Medicine"},{"key":"1901_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.exphem.2005.01.007","volume":"33","author":"JM Gall","year":"2005","unstructured":"Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG: T cells armed with anti-CD3\u2009\u00d7\u2009anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol. 2005, 33: 452-459.","journal-title":"Exp Hematol"},{"key":"1901_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1078-0432.CCR-05-1855","volume":"12","author":"U Reusch","year":"2006","unstructured":"Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY, Lum LG: Anti-CD3\u2009\u00d7\u2009anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers In vitro and in an animal model. Clin Cancer Res. 2006, 12: 183-190.","journal-title":"Clin Cancer Res"},{"key":"1901_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/15258160151134944","volume":"10","author":"M Sen","year":"2001","unstructured":"Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG: Use of anti-CD3 x anti-HER2\/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2\/neu\u2009+\u2009tumors. J Hematother Stem Cell Res. 2001, 10: 247-260.","journal-title":"J Hematother Stem Cell Res"},{"key":"1901_CR18","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s00262-011-1056-9","volume":"60","author":"A Thakur","year":"2011","unstructured":"Thakur A, Norkina O, Lum LG: In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells. Cancer Immunol Immunother. 2011, 60: 1707-1720.","journal-title":"Cancer Immunol Immunother"},{"key":"1901_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1479-5876-11-35","volume":"11","author":"A Thakur","year":"2013","unstructured":"Thakur A, Schalk D, Tomaszewski E, Kondadasula SV, Yano H, Sarkar FH, Lum LG: Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway. J Transl Med. 2013, 11: 35-","journal-title":"J Transl Med"},{"key":"1901_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2407-13-83","volume":"13","author":"IM Zitron","year":"2013","unstructured":"Zitron IM, Thakur A, Norkina O, Barger GR, Lum LG, Mittal S: Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer. 2013, 13: 83-","journal-title":"BMC Cancer"},{"key":"1901_CR21","first-page":"1","volume":"11","author":"CD Fryar","year":"2012","unstructured":"Fryar CD, Gu Q, Ogden CL: Anthropometric reference data for children and adults: United States, 2007\u20132010. Vital Health Stat. 2012, 11: 1-48.","journal-title":"Vital Health Stat"},{"key":"1901_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fonc.2013.00167","volume":"3","author":"V Pistoia","year":"2013","unstructured":"Pistoia V, Morandi F, Bianchi G, Pezzolo A, Prigione I, Raffaghello L: Immunosuppressive microenvironment in neuroblastoma. Front Oncol. 2013, 3: 167-","journal-title":"Front Oncol"},{"key":"1901_CR23","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1172\/JCI28828","volume":"116","author":"G Gallina","year":"2006","unstructured":"Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. The Journal of Clinical Investigation. 2006, 116: 2777-2790.","journal-title":"The Journal of Clinical Investigation"},{"key":"1901_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1155\/2011\/732413","volume":"2011","author":"C Jackson","year":"2011","unstructured":"Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M: Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol. 2011, 2011: 20-","journal-title":"Clin Dev Immunol"},{"key":"1901_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1365-2036.2006.03075.x","volume":"24","author":"C Evans","year":"2006","unstructured":"Evans C, Dalgleish AG, Kumar D: Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther. 2006, 24: 1163-1177.","journal-title":"Aliment Pharmacol Ther"},{"key":"1901_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1155\/2014\/686879","volume":"2014","author":"M Pancione","year":"2014","unstructured":"Pancione M, Giordano G, Remo A, Febbraro A, Sabatino L, Manfrin E, Ceccarelli M, Colantuoni V: Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis. J Immunol Res. 2014, 2014: 11-","journal-title":"J Immunol Res"},{"key":"1901_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","volume":"21","author":"LJ Bayne","year":"2012","unstructured":"Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012, 21: 822-835.","journal-title":"Cancer Cell"},{"key":"1901_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CJI.0b013e31823aa41c","volume":"35","author":"JS Weber","year":"2012","unstructured":"Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D: Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother. 2012, 35: 89-97.","journal-title":"J Immunother"},{"key":"1901_CR29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2007-11-125435","volume":"112","author":"B Kavanagh","year":"2008","unstructured":"Kavanagh B, O\u2019Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L: CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008, 112: 1175-1183.","journal-title":"Blood"},{"key":"1901_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/bmt.2013.133","volume":"49","author":"LG Lum","year":"2014","unstructured":"Lum LG, Thakur A, Pray C, Kouttab N, Abedi M, Deol A, Colaiace WM, Rathore R: Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin\u2019s lymphoma: a pilot study. Bone Marrow Transplant. 2014, 49: 73-79.","journal-title":"Bone Marrow Transplant"},{"key":"1901_CR31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.bbmt.2013.03.010","volume":"19","author":"LG Lum","year":"2013","unstructured":"Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L, Abidi MH, Pray C, Tomaszewski EN, Steele PA, Schalk DL, Yano H, Mitchell A, Dufresne M, Uberti JP, Ratanatharathorn V: CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2013, 19: 925-933.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1901_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1158\/1078-0432.CCR-05-2005","volume":"12","author":"RC Grabert","year":"2006","unstructured":"Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG: Human T cells armed with Her2\/neu bispecific antibodies divide, Are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res. 2006, 12: 569-576.","journal-title":"Clin Cancer Res"},{"key":"1901_CR33","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/pbc.24237","volume":"59","author":"M Yankelevich","year":"2012","unstructured":"Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG: Anti-CD3\u2009\u00d7\u2009anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer. 2012, 59: 1198-1205.","journal-title":"Pediatr Blood Cancer"},{"key":"1901_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","volume":"31","author":"EO Long","year":"2013","unstructured":"Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S: Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013, 31: 227-258.","journal-title":"Annu Rev Immunol"},{"key":"1901_CR35","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00018-012-0968-7","volume":"69","author":"O Boyman","year":"2012","unstructured":"Boyman O, Krieg C, Homann D, Sprent J: Homeostatic maintenance of T cells and natural killer cells. Cell Mol Life Sci. 2012, 69: 1597-1608.","journal-title":"Cell Mol Life Sci"},{"key":"1901_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2567.2010.03308.x","volume":"131","author":"CA Lindqvist","year":"2010","unstructured":"Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Stromberg U, Loskog AS: T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology. 2010, 131: 371-376.","journal-title":"Immunology"},{"key":"1901_CR37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J: The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012, 12: 180-190.","journal-title":"Nat Rev Immunol"},{"key":"1901_CR38","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","volume":"118","author":"ZZ Yang","year":"2011","unstructured":"Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, Novak AJ, Ansell SM: Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood. 2011, 118: 2809-2820.","journal-title":"Blood"},{"key":"1901_CR39","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1158\/0008-5472.CAN-05-4128","volume":"66","author":"R Kim","year":"2006","unstructured":"Kim R, Emi M, Tanabe K, Arihiro K: Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006, 66: 5527-5536.","journal-title":"Cancer Res"},{"key":"1901_CR40","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1073\/pnas.0914500107","volume":"107","author":"DG Brooks","year":"2010","unstructured":"Brooks DG, Walsh KB, Elsaesser H, Oldstone MB: IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection. Proc Natl Acad Sci U S A. 2010, 107: 3018-3023.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1901_CR41","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.1158\/1078-0432.CCR-04-0872","volume":"10","author":"S Beckebaum","year":"2004","unstructured":"Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, Grosse-Wilde H, Broelsch CE, Gerken G, Cicinnati VR: Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res. 2004, 10: 7260-7269.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-12-191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T18:33:30Z","timestamp":1746297210000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-12-191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,9]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1901"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-12-191","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,9]]},"assertion":[{"value":"18 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"191"}}